JP5055136B2 - Vegf−r2阻害剤としてのイミダゾ(1,2−a)ピリジン化合物 - Google Patents

Vegf−r2阻害剤としてのイミダゾ(1,2−a)ピリジン化合物 Download PDF

Info

Publication number
JP5055136B2
JP5055136B2 JP2007557126A JP2007557126A JP5055136B2 JP 5055136 B2 JP5055136 B2 JP 5055136B2 JP 2007557126 A JP2007557126 A JP 2007557126A JP 2007557126 A JP2007557126 A JP 2007557126A JP 5055136 B2 JP5055136 B2 JP 5055136B2
Authority
JP
Japan
Prior art keywords
mmol
pyridin
phenyl
group
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007557126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531574A (ja
JP2008531574A5 (https=
Inventor
デイビッド・アンソニー・バーダ
ティモシー・ポール・バークホルダー
ジョシュア・ライアン・クレイトン
ヤン・ハオ
ペリー・クラーク・ヒース
ジェイムズ・ロバート・ヘンリー
ジョン・モント・ノーベロッチ
デイビッド・メンデル
ジョナサン・アレキサンダー・マクリーン
デイビッド・マイケル・レミック
マーク・エドワード・レンパラ
チャオ−キン・ワン
イップ・イボンヌ・イー・マイ
チョン・ボユ
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2008531574A publication Critical patent/JP2008531574A/ja
Publication of JP2008531574A5 publication Critical patent/JP2008531574A5/ja
Application granted granted Critical
Publication of JP5055136B2 publication Critical patent/JP5055136B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2007557126A 2005-02-24 2006-02-23 Vegf−r2阻害剤としてのイミダゾ(1,2−a)ピリジン化合物 Expired - Fee Related JP5055136B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65598105P 2005-02-24 2005-02-24
US60/655,981 2005-02-24
PCT/US2006/006283 WO2006091671A1 (en) 2005-02-24 2006-02-23 Imidazo (1, 2-a) pyridine compounds as vegf-r2 inhibitors

Publications (3)

Publication Number Publication Date
JP2008531574A JP2008531574A (ja) 2008-08-14
JP2008531574A5 JP2008531574A5 (https=) 2009-04-02
JP5055136B2 true JP5055136B2 (ja) 2012-10-24

Family

ID=36587138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007557126A Expired - Fee Related JP5055136B2 (ja) 2005-02-24 2006-02-23 Vegf−r2阻害剤としてのイミダゾ(1,2−a)ピリジン化合物

Country Status (33)

Country Link
US (1) US7666879B2 (https=)
EP (1) EP1904494B1 (https=)
JP (1) JP5055136B2 (https=)
KR (1) KR100904938B1 (https=)
CN (1) CN101128461B (https=)
AR (1) AR056186A1 (https=)
AT (1) ATE490254T1 (https=)
AU (1) AU2006216710B2 (https=)
BR (1) BRPI0609047A2 (https=)
CA (1) CA2599124C (https=)
CR (1) CR9331A (https=)
CY (1) CY1111154T1 (https=)
DE (1) DE602006018615D1 (https=)
DK (1) DK1904494T3 (https=)
DO (1) DOP2006000051A (https=)
EA (1) EA011691B1 (https=)
ES (1) ES2354716T3 (https=)
HR (1) HRP20100677T1 (https=)
IL (1) IL184717A (https=)
MA (1) MA29433B1 (https=)
MX (1) MX2007010326A (https=)
NO (1) NO20074666L (https=)
NZ (2) NZ584753A (https=)
PE (1) PE20061098A1 (https=)
PL (1) PL1904494T3 (https=)
PT (1) PT1904494E (https=)
RS (1) RS51590B (https=)
SI (1) SI1904494T1 (https=)
TN (1) TNSN07323A1 (https=)
TW (1) TW200640924A (https=)
UA (1) UA91535C2 (https=)
WO (1) WO2006091671A1 (https=)
ZA (1) ZA200707136B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
HRP20150642T1 (hr) * 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
US20110105602A2 (en) 2007-03-08 2011-05-05 Daria Mochly-Rosen Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
AR068877A1 (es) * 2007-10-17 2009-12-09 Novartis Ag Derivados heterociclicos de imidazol
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
TW201124391A (en) 2009-10-20 2011-07-16 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US8680280B2 (en) * 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
JP6430383B2 (ja) * 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーVanderbilt University 選択的bmp阻害剤としての縮合複素環化合物
KR101735975B1 (ko) * 2012-11-29 2017-05-15 에프. 호프만-라 로슈 아게 이미다조피리딘 유도체
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CA2933811C (en) 2013-12-16 2021-02-09 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
CN103772308B (zh) * 2013-12-31 2015-11-18 北京颖泰嘉和生物科技股份有限公司 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法
US9988371B2 (en) 2014-06-03 2018-06-05 The Arizona Board Of Regents On Behalf Of The University Of Arizona Benzimidazole analogues and related methods
US10065934B2 (en) 2014-07-17 2018-09-04 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and pharmaceutical uses thereof
CN104163790B (zh) * 2014-08-19 2016-02-10 贵州威顿晶磷电子材料股份有限公司 一种2-氨基-4-甲基-5溴吡啶的制备工艺
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10730842B2 (en) 2015-09-03 2020-08-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
ES2904615T3 (es) * 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
WO2019178383A1 (en) 2018-03-14 2019-09-19 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
US10239885B1 (en) 2018-06-18 2019-03-26 Avista Pharma Solutions, Inc. Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist
SG11202106304RA (en) 2018-12-31 2021-07-29 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
BR112021013557A2 (pt) 2019-01-11 2021-09-21 Grünenthal GmbH Amidas de pirrolidina substituídas iii
CA3128024A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Chemical compounds
MX2021009251A (es) 2019-01-30 2021-09-21 Avista Pharma Solutions Inc Proceso de sintesis y nuevos compuestos intermedios.
EP3904355B1 (en) * 2019-02-18 2024-11-20 Shenzhen TargetRx, Inc. Substituted fused aromatic ring derivative, composition and use thereof
CN114466847A (zh) * 2019-06-25 2022-05-10 西诺普塞疗法公司 用于治疗癌症的化合物
CN112778294A (zh) * 2021-01-07 2021-05-11 苏州安睿药业有限公司 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用
TW202320796A (zh) 2021-08-11 2023-06-01 美商拜歐米富士恩股份有限公司 用於糖尿病的menin-mll相互作用之共價抑制劑
US12018032B2 (en) 2021-08-20 2024-06-25 Biomea Fusion, Inc. Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
WO2025038525A1 (en) * 2023-08-11 2025-02-20 Bioventures, Llc Fms-like tyrosine kinase 3 (flt3) inhibitors for treating cell proliferative diseases or conditions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2103097A (en) 1996-03-15 1997-10-10 Zeneca Limited Cinnoline derivatives and use as medicine
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2374737C (en) 1999-07-09 2008-02-12 Boehringer Ingelheim Pharmaceuticals, Inc. Novel process for synthesis of heteroaryl-substituted urea compounds
US6492529B1 (en) 2000-01-18 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Bis pyrazole-1H-pyrazole intermediates and their synthesis
WO2003005999A2 (en) 2001-07-11 2003-01-23 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
ATE381332T1 (de) * 2002-05-02 2008-01-15 Merck & Co Inc Tyrosinkinase-hemmer
US7550470B2 (en) * 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
AU2003298942A1 (en) * 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
EP1657242A4 (en) 2003-08-15 2008-10-29 Banyu Pharma Co Ltd imidazopyridine

Also Published As

Publication number Publication date
IL184717A (en) 2011-11-30
CR9331A (es) 2008-03-31
US20090227622A1 (en) 2009-09-10
TNSN07323A1 (en) 2008-12-31
AR056186A1 (es) 2007-09-26
HRP20100677T1 (hr) 2011-01-31
RS51590B (sr) 2011-08-31
PE20061098A1 (es) 2006-10-20
CY1111154T1 (el) 2015-06-11
AU2006216710A1 (en) 2006-08-31
DK1904494T3 (da) 2011-02-21
EP1904494B1 (en) 2010-12-01
US7666879B2 (en) 2010-02-23
TW200640924A (en) 2006-12-01
DOP2006000051A (es) 2006-08-31
NO20074666L (no) 2007-11-09
HK1118284A1 (en) 2009-02-06
EA011691B1 (ru) 2009-04-28
KR100904938B1 (ko) 2009-06-29
IL184717A0 (en) 2007-12-03
ES2354716T3 (es) 2011-03-17
AU2006216710B2 (en) 2011-08-11
KR20070099029A (ko) 2007-10-08
JP2008531574A (ja) 2008-08-14
PT1904494E (pt) 2010-12-23
SI1904494T1 (sl) 2011-02-28
CN101128461B (zh) 2010-12-22
PL1904494T3 (pl) 2011-04-29
UA91535C2 (en) 2010-08-10
DE602006018615D1 (de) 2011-01-13
CA2599124C (en) 2013-08-06
CN101128461A (zh) 2008-02-20
ZA200707136B (en) 2008-11-26
BRPI0609047A2 (pt) 2010-11-16
NZ584753A (en) 2011-06-30
WO2006091671A1 (en) 2006-08-31
EA200701802A1 (ru) 2008-02-28
ATE490254T1 (de) 2010-12-15
EP1904494A1 (en) 2008-04-02
MX2007010326A (es) 2007-10-16
MA29433B1 (fr) 2008-05-02
CA2599124A1 (en) 2006-08-31
NZ560402A (en) 2010-06-25

Similar Documents

Publication Publication Date Title
JP5055136B2 (ja) Vegf−r2阻害剤としてのイミダゾ(1,2−a)ピリジン化合物
JP6224095B2 (ja) ピリジノンおよびピリダジノン誘導体
RU2482112C2 (ru) Ингибиторы киназ, применимые для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний
JP6545199B2 (ja) 3−アミノ−1,5,6,7−テトラヒドロ−4h−インドール−4−オン類
JP5406030B2 (ja) 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ3阻害薬としての使用
US20130196952A1 (en) Heterocyclic derivatives for the treatment of diseases
US20230078764A1 (en) Compounds and uses thereof
RS54725B1 (sr) Benzen sulfonamid tiazol i jedinjenja oksazola
JP2021519263A (ja) 化合物及びその使用
CA3174845A1 (en) Substituted pyridines for the treatment of inflammatory diseases
CN110114343A (zh) 吡唑并嘧啶化合物及其使用方法
CN120344517A (zh) 作为pcsk9抑制剂的咪唑并[4,5-b]吡啶衍生物及其使用方法
US20240158385A1 (en) Novel compounds
HK1118284B (en) Imidazo[1,2-a]pyridine compounds as vegf-r2 inhibitors
US20250282794A1 (en) Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120724

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120730

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150803

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees